Vol 2, No 6 (2013)
Review article
Published online: 2013-12-30
The efficacy and safety of DPP-4 inhibitors considering cardiovascular risk factors
Diabetologia Kliniczna 2013;2(6):220-225.
Abstract
In most diabetic patients, cardiovascular diseases, especially myocardial infarction and cerebral stroke, remain the main cause of death. Thus, the control of risk factors, especially glycemic control, plays a key role in death prevention. Additional (other than hypoglycemic) effects of antidiabetic agents remain an open question. Currently available agents include the recently introduced class of DPP-4 inhibitors. Numerous clinical trials confirmed their efficacy in reducing glycemia and safety of use. There are reasons to argue that, in addition to hypoglycemic effect, inhibition of GLP-1 degradation may contribute to reducing the risk of cardiovascular complications. This paper is an overview of the present state of knowledge of the effect of GLP-1 and inhibition of its degradation on cardiovascular risk. The final settlement of this question will take place after publication of the results of large clinical trials assessing the effect ofDPP-4 inhibitors on the development of cardiovascular outcomes.
Keywords: type 2 diabeteshypoglycaemic agentscardiovascular riskDPP-4 inhibitors